Search PubMed⌕ Search

Biomedical subjects

S Sander

Publications and source records attributed to S Sander.

At least 19 recordsLinked to original sources
PubMed1991

Localized prostate carcinoma treated with TUR and neodymium-YAG laser irradiation.

Neodymium-YAG laser irradiation subsequent to extended transurethral resection has been practised in our department since 1981 as an alternative treatment for patients with localized prostate carcinoma. The treatment is performed endoscopically in two separate steps. The procedure is simple and complications are few. One hundred and twenty-four patients have been treated and followed up for more than 6 months. One hundred and ten patients are evaluated as disease free survivors and the overall actuarial disease free survival rate is 88% at 4-9 years of follow-up. The initial promising results persist and the results from other clinics confirm the method to be a fair alternative or patients with localized prostate carcinoma.

Humans↗
PubMed1990

Neodymium-YAG laser irradiation of stage T2 muscle-invasive bladder cancer. Long-term results.

The study group consisted of 15 patients with solitary stage T2 bladder tumours treated with transurethral resection (TUR) and subsequent neodymium-YAG laser irradiation. Ten patients are alive without evidence of cancer 56 to 78 months (mean 67) after treatment; 1 died of cardiovascular disease 2 years after treatment and autopsy revealed no cancer. In 4 patients the treatment failed and cystectomy or external beam radiation was carried out. The long-term results indicate the combination of TUR and laser irradiation to be beneficial in the management of T2 tumours in selected cases.

Aged↗
PubMed1990

A randomized study on hormone-resistant prostatic cancer: estramustine phosphate versus low dose epirubicin with or without medroxyprogesterone acetate. A Norwegian multicenter study.

A prospective randomized study has been carried out in order to compare three different treatment modalities for symptomatic metastatic hormone-resistant prostatic cancer. A total of 79 patients were included. One group was treated with estramustine phosphate, another with Epirubicin plus Medroxyprogesterone acetate (MPA), while the third arm consisted of Epirubicin plus placebo. Best palliation was obtained by the combination of Epirubicin and MPA. This combination also seemed to be associated with the longest response duration.

Administration, Oral↗
PubMed1989

Kinetic analysis and simulation of glucose transport in plasma membrane vesicles of glucose-repressed and derepressed Saccharomyces cerevisiae cells.

In this study experimental data on the kinetic parameters investigated by other authors 1-5, 11 together with own data on plasma membrane vesicles, have been subjected to a computer simulation based on the equations describing facilitated diffusion. The simulation led to an ideal fit describing the above data. From this it can be concluded that glucose is transported by facilitated diffusion, and not by active transport as was postulated by Van Steveninck 14,15. The simulation method also demonstrates that the fast sampling technique used by these authors 1-5, 11 underestimated the fluxes. Thus, the parameters given do not contribute to the understand of glucose transport under different metabolic conditions. The K value of plasma membrane vesicles prepared from glucose-repressed cells is around 7 mM. Derepression, particularly by galactose, causes a highly significant increase in affinity as shown by a decrease in the K value to 2 mM. The highest affinity was measured in a triple kinaseless mutant grown on glycerol with a K value of 1 mM. It seems, therefore, that the kinetic parameters derived from initial uptake rates of glucose in intact cells 1-5, 11 using single flux analysis, such as Eadie-Hofstee- or Lineweaver-Burk-plots, are in error.

Biological Transport↗
PubMed1989

[Intravesical BCG vaccine in bladder cancer].

We present a preliminary report on intravesical BCG instillation in four patients. The indications are prevention of new superficial tumors and treatment of carsinoma in situ. 120 mg Connaught BCG-vaccine in 50 cc saline is instillated weekly for a total of six treatments. Follow-up was performed every three months and included cystoscopy and urine cytology. The prophylactic effect is encouraging, even in patients who have previously not responded to intravesical chemotherapy. There were no serious complications and the common side effects of fever and dysuria did not delay or interrupt treatment.

Administration, Intravesical↗
PubMed1987

Ketoconazole high dose in the hormonal treatment of advanced carcinoma of the prostate. A pilot study.

Five previously untreated patients with advanced carcinoma of the prostate were treated with the non-estrogenic antifungal agent Ketoconazole in high doses. A rapid fall in serum testosterone, adrenal androgens and serum prostatic acid phosphatases was recorded accompanied by a striking clinical response with reduction of skeletal pain and improvement of performance status. In one patient this was dramatically shown by reduction of a large pelvic tumor and associated edema of the left lower limb. Side-effects such as weakness, fatigue and loss of appetite made four of the patients withdraw from the study. Serum testosterone and serum prostatic acid phosphatase initially suppressed, increased slowly during the treatment period. Consequently, Ketoconazole as sole therapy in the treatment of advanced carcinoma of the prostate was stopped. However, the initial rapid decrease in serum testosterone and the striking positive clinical effect may possibly be utilized combined with orchiectomy or treatment with LHRH agonist analogues.

Adenocarcinoma↗
PubMed1986

First clinical experiences on neodymium-YAG laser irradiation of localized prostatic cancer.

This first clinical report on Neodymium-YAG laser irradiation of localized prostatic cancer presents our experiences in 63 patients during 4 years. Transurethral resection extending to the capsule and subsequent laser irradiation according to our standardized treatment procedure give few complications and good functional results. Actuarial disease-free survival is 98% on one year and 80% in the 2-4 year period. The results are promising and comparable to short-term results obtained by radiotherapy and/or interstitial radioactive implants. Further experience is necessary for a definitive comparison to established treatment modalities.

Aged↗
PubMed1985

Neodymium:YAG laser irradiation of urinary bladder tumors. Follow-up study of 100 consecutively treated patients.

Advanced laser beam technology has made endoscopic destruction of urinary bladder tumors possible. The neodymium: YAG laser is more suited for this purpose than the other available laser systems because of the higher penetration power into biological tissue. Small superficial tumors are particularly suitable for this treatment, but it is also possible to deal with muscle invasive tumors. The treatment procedure is simple and well tolerated by the patients. Recurrence of tumor in the irradiated area can be avoided by precise irradiation. In spite of being a no-touch technique, however, laser does not appear to prevent the occurrence of new tumors in nonirradiated areas.

Adult↗